BMCM
AKBA icon

Bryn Mawr Capital Management’s Akebia Therapeutics AKBA Stock Holding History

Bryn Mawr Capital Management’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-29,000
Closed -$267K – 73
2017
Q1 		$267K Hold
29,000
– – 0.27% 60
2016
Q4 		$302K Buy
+29,000
New +$250K 0.31% 56

Other funds holding AKBA

EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bryn Mawr Capital Management's AKBA Position: Q2 2017 in Review

Bryn Mawr Capital Management sold out of Akebia Therapeutics (AKBA) in Q2 2017, closing a stake of 29,000 shares — an estimated $267K sold.

Bryn Mawr Capital Management first reported a position in AKBA in Q4 2016 and held it in 2 quarters. The position peaked at $302K in Q4 2016. 118 funds tracked by Wall St. Rank hold AKBA as of Q2 2017.

  • Bryn Mawr Capital Management reported no remaining Akebia Therapeutics position as of Q2 2017 after selling out during the quarter.
  • Bryn Mawr Capital Management sold 29,000 Akebia Therapeutics shares in Q2 2017, an estimated $267K.
  • Bryn Mawr Capital Management first reported a position in Akebia Therapeutics in Q4 2016 and held it in 2 quarters.
  • Bryn Mawr Capital Management's Akebia Therapeutics position peaked at $302K in Q4 2016.
  • 118 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2017.

Based on Bryn Mawr Capital Management's 13F filing for Q2 2017, filed 11 Aug 2017.